Biosynch provides an AI-driven drug discovery platform that integrates multi‑omics, clinical and real‑world data into a unified computational substrate. Its deep‑learning models and generative chemistry engine predict and design candidate molecules with optimized efficacy, safety and manufacturability, delivering results via a secure cloud dashboard and API for pharma, biotech and academic R&D.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery relies on iterative, labor-intensive experiments and fragmented data sources, leading to long development timelines, high attrition rates, and limited ability to predict efficacy and safety early in the pipeline. The lack of integrated computational tools hampers the systematic exploration of vast chemical and biological spaces, especially for complex disease targets.
Solution
Biosynch offers an AI‑native drug discovery platform that unifies multi‑omics datasets, clinical records, and real‑world evidence into a single computational substrate. Advanced deep‑learning models predict drug‑target interactions with high fidelity, enabling rapid prioritization of candidate molecules. The platform then applies generative chemistry algorithms to design compounds optimized for potency, selectivity, safety, and manufacturability. An automated feedback loop links in‑silico predictions with wet‑lab validation, continuously refining model accuracy. All results are delivered through a secure, cloud‑based dashboard that supports API integration with existing R&D informatics systems, allowing teams to accelerate lead identification from years to months.
Target Audience
Primary customers are pharmaceutical R&D divisions, biotech firms, and academic drug‑discovery programs seeking to shorten lead‑generation cycles and improve hit‑to‑candidate success rates. The platform also serves contract research organizations that require scalable computational screening capabilities.
Features
- Deep‑learning ensembles for high‑resolution drug‑target interaction scoring across protein families
- Unified data lake integrating genomics, transcriptomics, proteomics, phenotypic screens, and electronic health record data
- Generative molecular design engine that optimizes ADMET properties and synthetic accessibility in a single step
- Closed‑loop workflow that automatically routes top predictions to high‑throughput assay pipelines and feeds experimental outcomes back into model training
- Scalable cloud infrastructure with GPU‑accelerated compute, supporting parallel screening of millions of virtual compounds
- RESTful API and FHIR‑compatible endpoints for seamless integration with LIMS, ELN, and corporate data warehouses
- End‑to‑end encryption and role‑based access controls to ensure compliance with HIPAA and GDPR regulations